| Literature DB >> 29284525 |
John W Frew1,2, Mark Davidson3, Dedee F Murrell4,5.
Abstract
BACKGROUND: Health Related Quality of Life (HR-QoL) Patient reported outcome measures (PROMs) have high utility in evaluation of new interventions in genodermatoses, however inconsistent standards of development and validation have hampered widespread acceptance and adoption.Entities:
Keywords: COSMIN checklist; Genodermatoses; Measurement properties; Patient reported outcome measures; Quality of life
Mesh:
Year: 2017 PMID: 29284525 PMCID: PMC5747090 DOI: 10.1186/s13023-017-0739-5
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Definitions of Important Measurement Properties: Comparison of the COSMIN Taxonomy and Definitions and Quality Criteria for Measurement Properties Definitions [7–9]
| Measurement Property | COSMIN Definition [ | Quality Criteria for Measurement Properties Definition [ |
|---|---|---|
| Content Validity | The degree to which the content of an HR-PRO instrument is an adequate reflection of the construct to be measured | The extent to which the domain of interest is comprehensively sampled by the items in the questionnaire |
| Internal Consistency | The degree of the interrelatedness among the items | The extent to which items in a (sub)scale are intercorrelated, thus measuring the same construct |
| Criterion Validity | The degree to which the scores of an HR-PRO instrument are an adequate reflection of a ‘gold standard’ | The extent to which scores on a particular questionnaire relate to a gold standard |
| Construct Validity | The degree to which the scores of an HR-PRO instrument are consistent with hypotheses (for instance with regard to internal relationships, relationships to scores of other instruments, or differences between relevant groups) based on the assumption that the HRPRO instrument validly measures the construct to be measured | The extent to which scores on a particular questionnaire relate to other measures in a manner that is consistent with theoretically derived hypotheses concerning the concepts that are being measured |
| Structural Validity | The degree to which the scores of an HR-PRO instrument are an adequate reflection of the dimensionality of the construct to be measured | |
| Hypothesis Testing (Aspect of Construct Validity) | Item construct validity | |
| Cross Cultural Validity (Aspect of Construct Validity) | The degree to which the performance of the items on a translated or culturally adapted HR-PRO instrument are an adequate reflection of the performance of the items of the original version of the HR-PRO instrument | |
| Reproducibility | ||
| Agreement | The systematic and random error of a patient’s score that is not attributed to true changes in the construct to be measured | The extent to which the scores on repeated measures are close to each other (absolute measurement error) |
| Reliability | The proportion of the total variance in the measurements which is due to ‘true’† differences between patients | The extent to which patients can be distinguished from each other, despite measurement errors (relative measurement error) |
| Responsiveness | The ability of an HR-PRO instrument to detect change over time in the construct to be measured | The ability of a questionnaire to detect clinically important changes over time |
| Floor and Ceiling Effects | (Not Defined) | The number of respondents who achieved the lowest or highest possible score |
| Interpretability | Interpretability is the degree to which one can assign qualitative meaning - that is, clinical or commonly understood connotations – to an instrument’s quantitative scores or change in scores. | The degree to which one can assign qualitative meaning to quantitative scores |
Inclusion and Exclusion Criteria for this Review
| Inclusion Criteria: |
| Disease is a Monogenic Inherited Disorder |
| Exclusion Criteria |
| Studies not investigating HR-QoL as a major outcome |
Fig. 1Flow Diagram of Literature Search and Systematic Review
Critical evaluation of development of Disease-Specific PROM using COSMIN criteria examined in this review
| Condition | HR-QoL PROM | Study | Items | CTT / IRT | Internal Consistency | Reliability | Measurement Error | Content Validity | Structural Validity | Hypothesis Testing | Cross Cultural Validity | Criterion Validity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congenital Ichthyosis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Pachyonychia Congenita |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Darier Disease |
|
|
|
|
|
|
|
|
|
|
|
|
| Neurofibromatosis Type 2 |
|
|
|
|
|
|
|
|
|
|
|
|
| HHT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Hereditary Angioedema |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| Epidermolysis Bullosa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Fabry Disease |
|
|
|
|
|
|
|
|
|
|
|
|
| Basal Cell Nevus Syndrome |
|
|
|
|
|
|
|
|
|
|
|
|
| Peutz Jegher Syndrome |
|
|
|
|
|
|
|
|
|
|
|
|
Abbreviations: IQOL (Ichthyosis QoL Questionnaire); FBI (Family Burden in Ichthyosis Questionnarie) IPCRR (International Pachynoychia Congenita Research Registry); DD-QOL (Darier Disease QoL Questionnaire); NFTI-QoL (Neurofibromatosis Type 2 Impact on QoL); HHT (Hereditary Haemorrhagic Telangiectasia); EQ-QOL (Epistaxis-specific QoL Questionnaire); IHAE-QoL (Inherited Angioedema QoL Questionnaire); FSPHPQ (Fabry Specific Pediatric Health and Pain Questionnaire) BCCNS (Basal Cell Carcinoma Nevus Syndrome); PJS (Peutz Jegher Syndrome)
Critical evaluation of Disease-Specific PROMs using “Quality criteria for measurement properties of health status questionnaires”
| Condition | HR-QoL PROM | Study | Content Validity | Internal Consistency | Criterion Validity | Construct Validity | Reproducibility | Responsiveness | Floor and Ceiling Effects | Interpretability | Score | Used in Studies? | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agreement | Reliability | ||||||||||||
| Congenital Ichthyosis |
|
| + | + (α = 0.94) |
| + | + |
| 0 | 0 | + (MIC = 9) |
|
|
|
|
| + | + (α = 0.89) |
| ? | + |
| 0 | 0 | + (MIC = 25) |
|
| |
| Pachyonychia Congenita |
|
| – | 0 |
| 0 | 0 |
| 0 | 0 | 0 |
|
|
|
|
| + | + |
| ? | ? |
| 0 | ? | 0 |
|
| |
| Darier Disease |
|
| + | 0 |
| ? | 0 |
| 0 | 0 | 0 |
|
|
| Neurofibromatosis Type 2 |
|
| + | + (α = 0.87) |
| + | 0 |
| 0 | 0 | ? |
|
|
| HHT |
|
| + | + (α = 0.95) |
| ? | + |
| 0 | 0 | + (MIC = 12) |
|
|
|
|
| – | 0 |
| 0 | 0 |
| 0 | 0 | 0 |
|
| |
| Hereditary Angioedema |
|
| + | -(α = 0.63–0.88) |
| ? | ? |
| 0 | 0 | 0 |
|
|
|
|
| + | 0 |
| 0 | 0 |
| 0 | 0 | 0 |
|
| |
| Epidermolysis Bullosa |
|
| + | + (α = 0.92) |
| + | + |
| 0 | ? | + (MIC = 6) |
|
|
|
|
| + | + (α = 0.9) |
| + | ? |
| 0 | 0 | 0 |
|
| |
| Fabry Disease |
|
| + | 0 |
| 0 | ? |
| 0 | 0 | 0 |
|
|
| Basal Cell Nevus Syndrome |
|
| + | + (α = 0.86–0.93) |
| + | ? |
| 0 | – | ? |
|
|
| Peutz Jegher Syndrome |
|
| + | – |
| ? | 0 |
| 0 | 0 | 0 |
|
|
Abbreviations: IQOL (Ichthyosis QoL Questionnaire), FBI (Family Burden in Ichthyosis Questionnarie) IPCRR (International Pachyonychia Congenita Research Registry), DD-QOL (Darier Disease QoL Questionnaire), NFTI-QoL (Neurofibromatosis Type 2 Impact on QoL), HHT (Hereditary Haemorrhagic Telangiectasia), EQ-QOL (Epistaxis-specific QoL Questionnaire), IHAE-QoL (Inherited Angioedema QoL Questionnaire), FSPHPQ (Fabry Specific Pediatric Health and Pain Questionnaire) BCCNS (Basal Cell Carcinoma Nevus Syndrome), PJS (Peutz Jegher Syndrome)
+ = Positive Rating? = Indeterminate Rating - = Negative Rating 0 = No Information available MIC = Minimal Important Change, α = Cronbach’s Alpha
(Four degrees of recommendation will be made: A) QoL measurement instrument meets all requirements and is recommended for use; B) QoL measure meets two or more quality items, but performance in all other required quality items is unclear, so that the outcome measure has the potential to be recommended in the future depending on the results of further validation studies; C) QoL measure has low quality in at least one required quality criterion (≥1 rating of “minus”) and therefore is not recommended to be used any more; D) QoL measure has (almost) not been validated. Its performance in all or most relevant quality items is unclear, so that it is not recommended to be used until further validation studies clarify its quality)